相关临床试验
278
29 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1839
进行中（未招募）
18
6.5%
已完成
184
66.2%
Enrolling By Invitation
3
1.1%
尚未招募
8
2.9%
招募中
25
9.0%
终止
24
8.6%
Unknown
1
0.4%
撤回
15
5.4%
暂无批准数据
- A multi-institutional team discovered MWAC-3634, a small molecule that blocks Ebola virus entry by stabilizing the viral entry protein rather than destabilizing it. - Screened from roughly 4.73 billion molecules using DNA-encoded chemistry, the compound inhibited authentic Ebola virus with an IC50 of 0.65 nM. - In a lethal mouse model, 85.7% of orally treated mice survived versus 28.6% of controls, with 100% survival among injected mice. - MWAC-3634 showed 69% oral bioavailability, but researchers caution it remains experimental and has not been tested or approved for human use.
- Researchers at Boston Medical Center and Boston University developed a scalable method to generate CD4+ helper T cells from induced pluripotent stem cells (iPSCs), overcoming a longstanding barrier in stem cell-based immunotherapy. - The protocol relies on removing Notch signaling during later maturation stages while reducing anti-T cell receptor signaling, enabling CD4+ T cells to survive and mature at scale. - The resulting T cells resemble those from blood with a full repertoire of subtypes, and the team's next step is to introduce a chimeric antigen receptor (CAR) and test cancer-killing ability in animal models. - The advance could support off-the-shelf CAR-T therapies that are ready when a patient is diagnosed, eliminating cell collection and individualized manufacturing.
- A four-year, $2.8 million NIH grant supports Boston University researchers investigating how the lung's microscopic structure shapes its response to inhaled particles. - The team's "crystal ribcage" imaging platform revealed that alveoli organize into "tiles" that consistently receive inhaled particles and neighboring "bands" that receive very little. - The project will examine whether tile and band alveoli differ in anatomy, oxygen levels, gene activity, and immune responses, with implications for respiratory disease and drug delivery. - Findings could reshape understanding of lung organization and inform aerosol-based drug delivery and development of new treatments.
- A study of 21,004 U.S. IVF embryo transfer cycles found higher cumulative clomiphene citrate doses raised miscarriage risk without improving live birth chances. - Women receiving 500–749 mg had a 12% higher miscarriage risk, while those receiving 750–999 mg had a 38% higher risk. - Women exposed to at least 750 mg were more than twice as likely to have twins or other multiple births. - Researchers urge clinicians to follow manufacturer safety recommendations and avoid unnecessarily increasing cumulative doses pending further study.
- A cohort study of nearly 20,000 NFL players found they were four times more likely to die from neurodegenerative diseases compared to the general population. - Players had 3.8-fold higher all-cause dementia mortality and 3.88-fold higher Parkinson's disease mortality, with rates remaining threefold higher after adjusting for known risk factors. - Those dying before age 60 showed more than 12-fold increased neurodegenerative death rates, and players with 5+ seasons had nearly double the risk versus those with shorter careers. - Researchers introduced the STARS effect concept, suggesting the fourfold increase may actually underrepresent the true risk given NFL players' otherwise superior health profiles.
- Owlstone Medical received up to $49.1 million from ARPA-H to develop the POSEIDON program, creating first-in-class synthetic-sensor based multi-cancer early detection tests for Stage I detection of 30+ solid tumors. - The innovative technology uses inhaled synthetic sensors that accumulate on cancer cells, with results detectable through breath and urine samples collected at home using portable devices. - The program aims to address the critical need for accessible cancer screening, as nearly 40% of Americans develop cancer and late-stage diagnoses cost significantly more than early detection. - The technology could restore up to $2.3 trillion to the U.S. economy by drastically reducing late-stage cancer diagnoses through early Stage I detection when treatment is most effective.
- Researchers from MIT, Massachusetts General Hospital, and Boston University propose a novel "Fund of Adaptive Royalties" (FAR) that finances half the cost of adaptive platform trials in exchange for future drug royalties. - The innovative financing model generated an expected return of 28% with a 22% probability of total loss in simulations based on HEALEY ALS Platform Trial data. - Adaptive platform trials allow multiple ALS drug candidates to be tested simultaneously under a single protocol, offering lower costs and shorter durations compared to traditional clinical trials. - The approach aims to address the funding bottleneck that has slowed ALS therapy development by attracting risk-tolerant investors like hedge funds and philanthropists.
- The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator has partnered with Siemens Healthineers to license the SpeechDx dataset, marking the first commercial partnership for this gold-standard speech and clinical data collection. - SpeechDx represents the largest longitudinal dataset combining harmonized speech, clinical, and biomarker data from approximately 2,000 participants across eight clinical sites, collected in three languages over three years. - The partnership aims to develop speech-based biomarkers that could detect Alzheimer's disease 20-30 years before symptoms appear, potentially transforming early diagnosis through accessible technology like smartphones and computers. - Data collection is scheduled to complete in 2028, with initial data releases to partners beginning in 2025, supporting the development of novel diagnostic and prognostic tools for Alzheimer's disease.
- The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications. - Research teams from seven prestigious institutions will investigate biological, clinical, and social factors influencing treatment response, using the AHA's Precision Medicine Platform for data analysis. - Studies will examine how GLP-1/GIP medications affect cardiovascular outcomes across different populations, with aims to develop more personalized treatment approaches and address health disparities.
